Valuation: Halozyme Therapeutics, Inc.

Market Cap 11.43B 10.36B 9.58B 8.65B 16.29B 1,078B 16.87B 115B 45.64B 576B 42.9B 41.99B 1,828B P/E 2026 *
13.7x
P/E 2027 * 10.9x
Enterprise Value 13.27B 12.03B 11.12B 10.04B 18.91B 1,251B 19.58B 134B 52.99B 668B 49.81B 48.75B 2,122B EV / Sales 2026 *
6.99x
EV / Sales 2027 * 5.52x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.40%
1 week-3.24%
Current month-23.41%
1 month-14.17%
3 months+1.63%
6 months+44.88%
Current year+48.99%
1 week 99.26
Extreme 99.26
105.64
1 month 99.26
Extreme 99.26
134
Current year 61.32
Extreme 61.325
134
1 year 61.22
Extreme 61.225
134
3 years 33.15
Extreme 33.15
134
5 years 29.85
Extreme 29.85
134
10 years 9.68
Extreme 9.68
134
Manager TitleAgeSince
Chief Executive Officer 63 06/01/2014
Director of Finance/CFO - 08/06/2026
Director of Finance/CFO 61 01/05/2013
Director TitleAgeSince
Director/Board Member 59 28/03/2013
Director/Board Member 63 06/01/2014
Chairman 61 -
Date Insider Type Main position Quantity % Market Cap. Importance
08/10/26 Exercice

Chief Executive Officer

60,000 0.0529%
01/10/26 Sell

Director

-5,230 0.0046%
01/10/26 Free

Director

2,944 0.0026%
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-3.24%+43.18%+148.87% 11.43B
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.20%+1.45%+36.17%+89.91% 431B
Weighted average by Cap. +0.54%+3.17%+37.71%+96.64%

Financials

2026 *2027 *
Net sales 1.9B 1.72B 1.59B 1.44B 2.71B 179B 2.8B 19.12B 7.58B 95.65B 7.13B 6.98B 304B 2.18B 1.98B 1.83B 1.65B 3.11B 206B 3.22B 21.96B 8.71B 110B 8.18B 8.01B 349B
Net income 906M 821M 760M 685M 1.29B 85.45B 1.34B 9.12B 3.62B 45.64B 3.4B 3.33B 145B 1.16B 1.05B 969M 874M 1.65B 109B 1.71B 11.64B 4.62B 58.22B 4.34B 4.25B 185B
Net Debt 1.84B 1.67B 1.54B 1.39B 2.62B 174B 2.72B 18.53B 7.35B 92.69B 6.91B 6.76B 294B 608M 551M 509M 460M 866M 57.31B 897M 6.12B 2.43B 30.61B 2.28B 2.23B 97.18B
Projected Income Statement - Annual - Halozyme Therapeutics, Inc.
Logo Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Employees
423
Date Price Change Volume
13/11/26 $100.27 -0.40% 2,276,409
12/11/26 $100.67 -0.99% 1,430,974
11/11/26 $101.68 -1.26% 2,505,104
10/11/26 $102.98 +0.06% 2,251,954
09/11/26 $102.92 -0.69% 2,926,864
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Halozyme Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
100.27USD
Average target price
119.89USD
Spread / Average Target
+19.57%
  1. Stock Market
  2. Stocks
  3. HALO Stock